The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid

Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC). The ATP-binding cassette (ABC) family of transporters includes P-glycoprote...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Invest New Drugs
Asıl Yazarlar: Karbownik, Agnieszka, Sobańska, Katarzyna, Płotek, Włodzimierz, Grabowski, Tomasz, Klupczynska, Agnieszka, Plewa, Szymon, Grześkowiak, Edmund, Szałek, Edyta
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2019
Konular:
Preclinical Studies
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211195/
https://ncbi.nlm.nih.gov/pubmed/31177402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00806-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller